Targeted treatment of non-small cell lung cancer

被引:0
|
作者
Scheffler, Matthias [1 ]
Michels, Sebastian [1 ]
Nogova, Lucia [1 ]
机构
[1] Univ Klinikum Koln AoR, Klin Innere Med 1, Ctr Integrierte Onkol CIO Aachen Bonn Koln Dussel, Lung Canc Grp Cologne, Kerpener Str 62, D-50937 Cologne, Germany
来源
INNERE MEDIZIN | 2022年 / 63卷 / 07期
关键词
Mutation; KRAS; EGFR; BRAF; Molecular genetic analysis; Drug resistance; neoplasm; OPEN-LABEL; ACQUIRED-RESISTANCE; INTEGRATED ANALYSIS; 1ST-LINE TREATMENT; EGFR MUTATIONS; CHEMOTHERAPY; MULTICENTER; CRIZOTINIB; PHASE-3; EFFICACY;
D O I
10.1007/s00108-022-01372-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-small cell lung cancer (NSCLC) has made a remarkable development in recent decades with respect to its perception. In the late 1990s it was the "problem child" as the main cause of cancer with increasing tendencies, especially in women and with a pronounced stigmatization. It is now the role model as a biologically rational targeted treatment based on molecular dependencies of the tumor with a vast improvement of the traditionally poor survival times. Molecular tumor boards have long followed the NSCLC example in the assessment of targeted treatment approaches for other tumor entities. This review article gives an overview of the current possibilities for targeted treatment of NSCLC, which nowadays are applicable for nearly one third of all patients with NSCLC.
引用
收藏
页码:700 / 708
页数:9
相关论文
共 50 条
  • [41] Novel chemoradiotherapeutic magnetic nanoparticles for targeted treatment of non-small cell lung cancer
    Munaweera, Imalka
    Yi, Shi
    Koneru, Bhuvaneswari
    Saez, Ruben
    Di Pasqua, Anthony J.
    Balkus, Kenneth J., Jr.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [42] Targeted therapies in the treatment of advanced non-small cell lung cancer elderly patients
    C. Gridelli
    P. Maione
    A. Rossi
    C. Ferrara
    G. Colantuoni
    F. Del Gaizo
    D. Nicolella
    C. Guerriero
    Targeted Oncology, 2006, 1 : 13 - 22
  • [43] Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics
    Guo, Matthew Z.
    Marrone, Kristen A.
    Spira, Alexander
    Waterhouse, David M.
    Scott, Susan C.
    ONCOTARGETS AND THERAPY, 2021, 14 : 5321 - 5331
  • [44] Diagnosis and treatment of lung cancer - Non-small cell lung cancer, small cell lung cancer and carcinoids
    End A.
    European Surgery, 2006, 38 (1) : 45 - 53
  • [45] Pembrolizumab for the treatment of non-small cell lung cancer
    Muller, Mirte
    Schouten, Robert D.
    De Gooijer, Cornedine J.
    Baas, Paul
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (05) : 399 - 409
  • [46] The treatment of advanced non-small cell lung cancer
    Spiro, SG
    Silvestri, GA
    CURRENT OPINION IN PULMONARY MEDICINE, 2005, 11 (04) : 287 - 291
  • [47] Radiation Treatment of Non-Small Cell Lung Cancer
    Zeng, Jing
    Rengan, Ramesh
    SEMINARS IN RADIATION ONCOLOGY, 2021, 31 (02) : 95 - 96
  • [48] On the pharmacogenetics of non-small cell lung cancer treatment
    Santarpia, Mariacarmela
    Rolfo, Christian
    Peters, G. J.
    Leon, Leticia G.
    Giovannetti, Elisa
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (03) : 307 - 317
  • [49] Treatment of non-small cell lung cancer (NSCLC)
    Zarogoulidis, Konstantinos
    Zarogoulidis, Paul
    Darwiche, Kaid
    Boutsikou, Efimia
    Machairiotis, Nikolaos
    Tsakiridis, Kosmas
    Katsikogiannis, Nikolaos
    Kougioumtzi, Ioanna
    Karapantzos, Ilias
    Huang, Haidong
    Spyratos, Dionysios
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S389 - S396
  • [50] Aptamers in Non-Small Cell Lung Cancer Treatment
    Wieleba, Irena
    Wojas-Krawczyk, Kamila
    Krawczyk, Pawel
    MOLECULES, 2020, 25 (14):